On November 13, 2024, Lilly announced the latest follow-up data of Phase III clinical SURBOUNT-1 of Tilpolide in the treatment of pre diabetes patients with obesity or overweight. The follow-up time was up to 3 years (176 weeks), and the data were also published in the New England Medical Journal.

After 176 weeks of treatment, the proportion of patients who progressed to type 2 diabetes in the Tilpodide treatment group and the placebo control group was 1.2% and 12.6% respectively, and the risk of progression to type 2 diabetes was reduced by 94%. After 17 weeks of drug withdrawal, the rates of progression to type 2 diabetes were 2.4% and 13.7%, respectively, and the risk of progression to type 2 diabetes was reduced by 88%. After drug withdrawal, the proportion of patients who progressed to type 2 diabetes increased rapidly, indicating that the disease progression was delayed but may not be fundamentally reversed. Nevertheless, it is still of great significance to delay the progress of type 2 diabetes.

In terms of weight, the placebo group, 5mg, 10mg, and 15mg tilbotide treatment groups lost 1.3%, 12.3%, 18.7%, and 19.7%, respectively.

GLP-1 has made breakthroughs in several indications, including glucose reduction, weight loss, sleep apnea, heart failure, CKD, cardiovascular protection, etc. The updated data of SURBOUNT-1 confirms that GLP-1 can not only continue to expand to the front line in the treatment of diabetes, but also move forward to the early stage of diabetes to prevent progression to diabetes.

Source: https://pharm.jgvogel.cn/c1461843.shtml